Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

The FDA has cleared its first completely at-home sexual health test for women, available over-the-counter to screen for ...

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) ...

Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases ...

The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH workers as part of an overarching move designed ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...

Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at the Massachusetts Institute of Technology in ...